Tag #Melanoma

Showing 25 to 28 of 28 results

dailymail.co.uk

🌐 75% Global Worthiness

Jan 23, 13:09

Mother of Four Battles Stage 4 Melanoma After Delayed Diagnosis

Kelly Heather, 38, from Kent, UK, is battling stage 4 metastatic melanoma after a dark line on her fingernail, initially dismissed, proved to be aggressive skin cancer that spread to her brain; her case highlights the importance of early detection and persistent advocacy for additional testing in ca...

Mother of Four Battles Stage 4 Melanoma After Delayed Diagnosis

Kelly Heather, 38, from Kent, UK, is battling stage 4 metastatic melanoma after a dark line on her fingernail, initially dismissed, proved to be aggressive skin cancer that spread to her brain; her case highlights the importance of early detection and persistent advocacy for additional testing in ca...

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the immediate consequences of delayed diagnosis in aggressive skin cancer cases like Kelly Heather's, and what systemic changes could improve early detection?

Kelly Heather, a 38-year-old mother of four, was diagnosed with stage 4 metastatic melanoma after initially noticing a dark line on her fingernail in 2017. Despite multiple treatments, the cancer spread to her brain, leaving her with a 50% chance of survival from her current treatment and facing the possibility of the cancer spreading to her newborn child.

napoli.repubblica.it

🌐 85% Global Worthiness

Dec 4, 19:09

Oncolytic Virus Immunotherapy Shows Promise for Advanced Melanoma

In a phase 2 clinical trial, combining the oncolytic virus immunotherapy RP1 with nivolumab resulted in a 30% overall response rate and 15% complete response rate in 140 patients with advanced melanoma unresponsive to prior immunotherapy, leading to FDA Breakthrough Therapy designation.

Oncolytic Virus Immunotherapy Shows Promise for Advanced Melanoma

In a phase 2 clinical trial, combining the oncolytic virus immunotherapy RP1 with nivolumab resulted in a 30% overall response rate and 15% complete response rate in 140 patients with advanced melanoma unresponsive to prior immunotherapy, leading to FDA Breakthrough Therapy designation.

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the mechanism of action of RP1, and what are its immediate impacts on advanced melanoma patients?

A genetically modified herpes simplex virus injected into melanoma eliminates cancer cells directly and indirectly by releasing molecules that stimulate the immune system. This mechanism is the basis of RP1, a new oncolytic virus immunotherapy. When combined with nivolumab, it shows promise for a third of patients with advanced melanoma unresponsive to standard immunotherapy.

smh.com.au

🌐 85% Global Worthiness

Dec 14, 22:08

Australia's Declining Melanoma Risk in Youth Threatened by Social Media

Australia's melanoma rates, while high, show a decreased risk in younger people since the 1990s, countered by a new social media trend promoting tanning, prompting a new sun safety campaign.

Australia's Declining Melanoma Risk in Youth Threatened by Social Media

Australia's melanoma rates, while high, show a decreased risk in younger people since the 1990s, countered by a new social media trend promoting tanning, prompting a new sun safety campaign.

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the impact of social media on the progress made in reducing melanoma rates in young Australians?

Despite Australia having the world's highest melanoma incidence, the risk of developing melanoma by age 30 has halved since 1997, reaching one in 1170 in 2020. This positive trend, however, is threatened by rising anti-sun safety messaging on social media.

pda.kp.ru

🌐 85% Global Worthiness

Dec 1, 19:16

Gamaleya Institute's mRNA Cancer Vaccine Shows Promise in Preclinical Trials

Preclinical trials of Gamaleya Research Institute's mRNA melanoma vaccine show tumor and metastasis regression in animals; human trials are planned for autumn 2025, initially combining the vaccine with other therapies for advanced cancers; future development aims for personalized, affordable vaccine...

Gamaleya Institute's mRNA Cancer Vaccine Shows Promise in Preclinical Trials

Preclinical trials of Gamaleya Research Institute's mRNA melanoma vaccine show tumor and metastasis regression in animals; human trials are planned for autumn 2025, initially combining the vaccine with other therapies for advanced cancers; future development aims for personalized, affordable vaccine...

Progress

56% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How will the vaccine be used in clinical trials, and what are the plans for future research directions?

The Gamaleya Institute is developing a personalized mRNA vaccine against melanoma that targets both the primary tumor and metastases. Successful preclinical results indicate potential for treating various cancers, including lung, kidney, and brain cancers, although further research is needed.

Showing 25 to 28 of 28 results